Provectus Biopharmaceuticals, Inc.
PVCT
$0.0799
-$0.0024-2.92%
OTC PK
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -79.36% | 1,848.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -79.36% | 1,848.25% | |||
| Cost of Revenue | 125.61% | -30.55% | |||
| Gross Profit | -685.69% | 80.90% | |||
| SG&A Expenses | -0.08% | -49.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 38.04% | -45.06% | |||
| Operating Income | -71.52% | 56.98% | |||
| Income Before Tax | -59.44% | 51.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -59.44% | 51.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 75.35% | -- | |||
| Net Income | -59.14% | 52.43% | |||
| EBIT | -71.52% | 56.98% | |||
| EBITDA | -71.54% | 56.99% | |||
| EPS Basic | -59.26% | 52.63% | |||
| Normalized Basic EPS | -66.67% | 57.14% | |||
| EPS Diluted | -59.26% | 52.63% | |||
| Normalized Diluted EPS | -66.67% | 57.14% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||